World Health Organisation (WHO) says it is working with partners on renaming Monkeypox and its variants, and also to put in place a mechanism to help share available vaccines, more equitably, as the need arises.
WHO Director General, Dr Tedros Ghebreyesus, disclosed this at a news conference on Tuesday in Geneva.
‘In the context of the current global outbreak, continued reference to, and nomenclature of this virus being African is not only inaccurate but is also discriminatory and stigmatising,’ they wrote.
The current naming system for monkeypox divides it into two types, the West African version and and the Central African/Congo Basin version, wit the current outbreak believed to be more closely related to the West African virus.
Giving geographic names to viruses and diseases is against WHO best practice guidelines as this can have negative consequences for countries where new infections are spotted or cause discrimination certain populations.
Instead the 30 scientists suggest renaming monkeypox to MPXV and following this classification with a number indicating the clade and listing them in order of discovery.
This would mean MPXV1 would be the new term for the West African version, MPXV2 the Central African one, and MPXV3 would be the name for the virus and disease currently spreading in multiple countries including the UK.
He said WHO had published guidelines on vaccination against Monkeypox and also published recommendations for governments regarding case detection and control of the disease.
Speaking to journalists in Geneva, WHO Smallpox expert, Dr Rosamund Lewis, said it was crucial to raise awareness in the population about the level of risk and explain the recommendations to avoid infecting close contacts and family members.
Lewis explained that although the disease sometimes only produced mild symptoms, such as skin lesions, it could be contagious for two to four weeks
“We know that it is very difficult for people to isolate themselves for so long, but it is very important to protect others.
“In most cases, people can self-isolate at home and there is no need to be in the hospital,” she said.
Monkeypox is transmitted through close physical contact with someone who has symptoms.
The rash, fluids, and scabs are especially infectious. Clothing, bedding, towels, or objects such as eating utensils or dishes that have been contaminated with the virus can also infect others.
However, it is not clear whether people who do not have symptoms can spread the disease, the expert reiterated.
While some countries have maintained strategic supplies of older smallpox vaccines – a virus eradicated in 1980 – these first-generation vaccines held in national stockpiles are not recommended for Monkeypox at this time.
This is because they do not meet the current safety and manufacturing standards.
Newer and safer (second and third generation) smallpox vaccines are also available, some of which may be useful for Monkeypox and one of which (MVA-BN) has been approved for the prevention of the disease.
According to the UN health agency, the supply of these new vaccines is limited, and access strategies are being discussed.
“At this time, the WHO does not recommend mass vaccination.
“Decisions about the use of smallpox or Monkeypox vaccines should be based on a full assessment of the risks and benefits in each case,” the guidelines indicate.
For the contacts of sick patients, post-exposure prophylaxis with a second- or third-generation vaccine is recommended, ideally within four days of first exposure to prevent disease onset.
Pre-exposure prophylaxis is recommended for healthcare workers at risk, laboratory personnel working with orthopoxviruses, clinical laboratory personnel performing diagnostic tests for Monkeypox, and others who may be at risk.
Lewis explained that most of the data on the smallpox vaccine was old or from animal studies. “There aren’t a lot of [current] clinical studies,” she said.
WHO underlined the importance of vaccination programme being supported by comprehensive surveillance and contact tracing, and accompanied by information campaigns and robust “pharmacovigilance”, ideally with collaborative studies on vaccine efficacy.
Courtesy: Agency Reports